Document:

Exhibit
10.2

 

UNSECURED
CONVERTIBLE PROMISSORY NOTE

 

	US$500,000.00	___________,
    2022

 

FOR
VALUE RECEIVED ONCOTELIC THERAPEUTICS, INC., a Delaware Corporation (the “Company”), promises to pay to Golden Mountain
Partners, LLC, a California Limited Liability Company (the “Holder”), in lawful money of the United States of America,
the principal amount of FIVE HUNDRED THOUSAND DOLLARS (US$500,000), together with interest on the unpaid principal balance, in the manner
provided below.

 

1.
Purchase Agreement. This unsecured convertible promissory note (the “Note”) is issued to Holder pursuant to
the terms of that certain Unsecured Convertible Note Purchase Agreement between Company and Holder, of even date herewith, as it may
be amended from time to time (the “Agreement”).

 

2. Draws. Subject to the terms and conditions set forth in this Note and the Agreement, Holder shall disburse to Company an aggregate
disbursement of US$500,000, on the dates and in the instalment amounts set forth in Schedule 3.2 (Disbursements) of the
Agreement.

 

3.
Maturity. Unless sooner paid or converted in accordance with the terms hereof, the entire unpaid principal balance of the Note
and all unpaid accrued interest thereon shall become fully due and payable on (a) the one year anniversary of the date of the Agreement,
or (b) the acceleration of the maturity of this Note by Holder upon occurrence of an Event of Default (as defined below) (such date,
the “Maturity Date”).

 

4. Payments.

 

(a) Form
of Payment. All payments of interest and principal (other than payment by way of conversion) shall be in lawful money of the
United States of America to Holder, by ACH transfer according to Receiving Bank and ABA Routing Number information as may be
specified from time to time by Holder.

 

(b) Interest Payments. Company shall pay to Holder accrued but unpaid interest upon the payment of the full outstanding principal
amount.

 

(c) Prepayment. Company shall have the right to prepay any and all amounts owed under this Note in whole or in part at any time subject
to Section 6 (Conversion Right) below, provided that any such prepayment amount must be accompanied by the accrued and unpaid
interest on the principal being prepaid through the date of prepayment.

 

5.
Interest. Interest shall accrue on the unpaid principal balance of this Note at the rate of two percent (2%) per annum. Interest
shall be calculated on the basis of a year of 365 days, and charged for the actual number of days elapsed. Interest shall commence with
the date hereof and shall continue on the outstanding principal of this Note until paid or converted in accordance with the provisions
hereof.

 

6. Conversion Right. At any time prior to repayment of this Note, Holder may elect, in lieu of repayment, to convert all or a portion
of the outstanding principal on this Note into that number of shares of Common Stock of Company equal to the quotient obtained by dividing
(a) 100.0% of the principal on this Note being converted by (b) the Conversion Price (as hereinafter defined). Holder will inform Company
of such election by delivering to Company this Note and a Notice of Conversion, the form of which is attached hereto as Schedule A
(a “Notice of Conversion”). If Holder delivers the Notice of Conversion to Company, Company may not elect to pay
Holder the amount of this Note to be converted without Holder’s written consent.

 

    	1

    	 

    

 

For
purposes of this Note, “Conversion Price” means the consolidated closing bid price of Company’s Common Stock
as determined by applicable OTC rules (or exchange where the Common Stock of Company is then traded), as of the date Company receives
a Notice of Conversion from Holder.

 

Holder
shall effect conversions by delivering to Company a Notice of Conversion accompanied by this Note, specifying therein the principal amount
of this Note to be converted. The date on which such conversion shall be effected (such date, the “Conversion Date”)
shall be the date of Company’s actual receipt of a Notice of Conversion, accompanied by this Note unless Company and Holder agree
in writing to another date. Conversions hereunder shall have the effect of lowering the outstanding principal amount of this Note in
an amount equal to the applicable principal amount converted. If less than the entire principal amount of this Note is converted, Company
will promptly issue a new Note to Holder representing the balance of this Note. From and after the Conversion Date, the portion of this
Note converted shall represent and be enforceable only as to the right to receive the shares of Common Stock issuable upon such conversion.

 

Promptly
after receipt of a Notice of Conversion, Company shall issue and deliver to Holder, but only against delivery of and after receiving
the original of this Note (or a lost note affidavit in the form and substance reasonably acceptable to Company), one or more certificates
representing such shares of Common Stock issued and registered as set forth in the Notice of Conversion. Thereupon, Company shall have
no further obligation with respect to the principal amount of this Note converted. ln lieu of issuing a fraction of a share of Common
Stock upon the conversion of this Note, Company shall pay Holder for any fraction of a share of Common Stock otherwise issuable upon
the conversion of this Note, cash equal to the same fraction of the then current per share Conversion Price.

 

 7. [Intentionally omitted.]

 

8. Events of Default. For purposes of this Note, the occurrence of any of the following events shall constitute an “Event
of Default”:

 

(a) Any indebtedness under this Note is not paid when and as the same shall become due and payable, whether at maturity, by acceleration,
or otherwise, and any such amount shall remain unpaid for a period of five (5) days after delivery to Company of notice of nonpayment;
or

 

(b) Any breach or default by Company in the performance of any term, covenant, agreement, condition, undertaking or provision of any Loan
Document (as such term is defined in the Agreement); or

 

    	2

    	 

    

 

 (c) Company’s breach of or failure to observe or comply with Section 5.2.1 (Loan Proceeds and Distributions) of the Agreement; or

 

(d) Company (i) is unable to pay its debts generally as they become due; (ii) files a petition in bankruptcy or a petition to take advantage
of any insolvency act; (iii) makes an assignment of its property for the benefit of its creditors; (iv) applies for or consent to the
appointment of a receiver, trustee, custodian or liquidator of itself or of the whole or any substantial part of its property; (v) files
a petition or answer seeking reorganization or arrangement under the federal bankruptcy laws or any other applicable law or statute of
the United States of America or any state thereof; (vi) is declared insolvent according to any law; or a receiver or trustee is appointed
for Company or its property; or the interest of Company under this Note is levied on under execution or other legal process; or any petition
is filed by or against Company to declare Company bankrupt or to delay, reduce or modify Company’s capital structure if the Company
be a corporation or other entity; (vii) after a petition in bankruptcy is filed against it, is adjudicated a bankrupt, or if a court
of competent jurisdiction shall enter an order or decree appointing, without the consent of Company, as the case may be, a receiver of
Company or of the whole or substantially all of its property, or approving a petition filed against it seeking reorganization or arrangement
of Company under the federal bankruptcy laws or any other applicable law or statute of the United States of America or any state thereof,
and such judgment, order or decree shall not be vacated or set aside or stayed within thirty (30) days from the date of the entry thereof;
or

 

(e)
At any time there occurs a Change in Control Transaction. For purposes of this Note, a “Change in Control
Transaction” means (i) a sale, lease or other disposition of assets or properties of Company or its subsidiaries
(calculated on a consolidated basis) having a book value of fifty-one percent (51%) or more of the book value of all the assets and
properties thereof, or (ii) any transaction in which any person or entity shall directly or indirectly acquire from the holders
thereof, by purchase or in a merger, consolidation or other transfer or exchange of outstanding capital stock, ownership or control
over capital stock of Company or any of its subsidiaries (or securities exchangeable for or convertible into such stock or
interests) entitled to elect a majority of such entity’s Board of Directors or representing at least fifty-one percent (51%)
of the number of shares of Common Stock outstanding; or

 

(f)
Company is liquidated or dissolved, or shall begin proceedings toward such liquidation or dissolution, or shall, in any manner, permit
the sale or divestiture of substantially all of its assets other than in connection with a merger or consolidation of Company into, or
a sale of substantially all of Company’s assets to, another corporation or entity; or

 

(g) On or at any time after the date of this Note any of the Loan Documents for any reason, other than a full release in accordance with
the terms thereof, ceases to be in full force and effect or is declared to be null and void; or

 

(h) This Note or any other Loan Document shall at any time for any reason cease to be valid, or Company or any subsidiary of Company contests
the validity or enforceability of any Loan Document in writing or denies that it has further liability under any Loan Document to which
it is party, or gives notice to such effect.

 

9. Remedies Upon Event of Default; Acceleration. If an Event of a Default shall occur for any reason, whether voluntary or involuntary,
and be continuing, Holder may, upon notice or demand to Company, declare the outstanding indebtedness under this Note to be due and payable,
whereupon the outstanding indebtedness under this Note shall be and become immediately due and payable, and Company shall immediately
pay to Holder all such indebtedness.

 

10. Governing Law. This Note shall be governed, construed and interpreted in accordance with the laws of the State of California,
without giving effect to principles of conflicts of law or choice of law that would cause the substantive laws of any other jurisdiction
to apply. Company irrevocably submits and consents to the jurisdiction of any California state court or federal court sitting in the
County of Los Angeles, State of California over any action or proceeding arising out of or relating to this Note or any other Loan Document
, and Company hereby irrevocably agrees that all claims in respect of any such action or proceeding may be heard and determined in such
courts.

 

11. Amendment. Any
term of this Note may be amended and the observance of any term of this Note may be waived (either generally or in a particular
instance and either retroactively or prospectively), only with the written consent of Company and Holder.

 

12. Notices. Except as may otherwise be provided herein, all notices, requests, waivers and other communications made pursuant to
this Note shall be made in accordance with Section 8.4 (Notices) of the Agreement.

 

13. Severability. If any provision of this Note is held invalid or unenforceable by any court of competent jurisdiction, the other
provisions of this Note will remain in full force and effect. Any provision of this Note held invalid or unenforceable only in part or
degree will remain in full force and effect to the extent not held invalid or unenforceable.

 

    	3

    	 

    

 

IN
WITNESS WHEREOF, Company has executed and delivered this Note as of the date first stated above.

 

	 	ONCOTELIC
    THERAPEUTICS, INC. (“COMPANY”)
	 	 	                          
	 	By:	/s/
    Vuong Trieu
	 	Name:	Vuong
    Trieu, PhD
	 	Title:	Chief
    Executive Officer

 

    	4

    	 

    

 

Schedule
A

Notice
of Conversion

 

The
undersigned, the Holder of the Note issued by Oncotelic Therapeutics, Inc. (which is attached to this Notice of Conversion), hereby elects
to convert the below stated outstanding principal portion of the Note into shares of Common Stock of Oncotelic Therapeutics, Inc., on
the terms and subject to the conditions of the Note, effective as of the date Company receives this Notice.

 

Please
send a certificate for the appropriate number of shares of Common Stock and a balance Note (if applicable) to the following address:

 

	 	Holder:	Golden
    Mountain Partners, LLC
	 	 	c/o
    Synergy Healthcare Innovations, LLC 800 W. Sixth Street, Suite 900
	 	 	Los
    Angeles, California 90017

 

Principal
Amount of Note Being Converted: $______________________

 

Register
and issue certificates for shares of Common Stock in the following name at the address set forth above.

 

	 	GOLDEN MOUNTAIN PARTNERS, LLC
	 	(“HOLDER”)
	 	
	 	By:	              
	 	Name:	 
	 	Title:
    	 
	 	Date:	 
	 	 	 

	 	Tax
    Identification Number: 37-1664077

 

    	5EX-10.1

 Exhibit 10.1 

RETENTION COMPENSATION AND AMENDMENT TO EMPLOYMENT AGREEMENT 

This Retention Compensation and Amendment to Employment Agreement (the “Agreement”) is dated January 28, 2022 and is by
and between Allena Pharmaceuticals, Inc. (the “Company”) and Louis Brenner, M.D. (the “Executive”) (together, the “Parties”). 

WHEREAS, the Company is in the process of pursuing various strategic alternatives, including without limitation a merger or restructuring (the
“Transition”); 
 WHEREAS, in the Executive’s position, Executive has obtained significant knowledge and expertise
about the Company and its business operations; 
 WHEREAS, in order to complete any strategic alternatives as part of the Transition, the
Company desires to continue to retain the services of Executive and the benefits of Executive’s experience and knowledge; 
 WHEREAS,
the Company recognizes the effort and commitment required of Executive to complete any transactions as part of the Transition and wants to create an incentive for Executive to continue to be employed by the Company during the Transition; 

WHEREAS, in light of the anticipated Transition and the Company’s current business needs, the Executive agrees to amend certain terms of
Executive’s employment under the Executive’s Amended and Restated Employment Agreement with the Company dated January 4, 2019 (the “Employment Agreement”) as provided in this Agreement; 

WHEREAS, the Executive desires to continue to perform services for the Company in accordance with the terms set forth below; 

WHEREAS to avoid doubt, except as expressly amended herein, the Employment Agreement and the “Restrictive Covenant
Obligations” (as defined in the Employment Agreement) shall remain in full effect. 
 NOW, THEREFORE, in return for good and
valuable consideration, the sufficiency of which is hereby acknowledged and agreed, the Parties hereby agree as follows: 
  

	1.	 Retention Compensation. 

 

	 	a.	 The Company will pay the Executive a lump sum retention payment (the “Retention Payment”)
equal to $376,600 in February, 2022. 

  

	 	b.	 The Company will increase the Executive’s current Base Salary (as defined in the Employment Agreement) by
6.5% (the “Salary Increase”). The Salary Increase shall be retroactive and effective as of January 1, 2022. 

  

	 	c.	 The Company will promptly grant the Executive 655,000 restricted stock units under the Company’s equity
plan (the “Retention Grant,” and together with the Retention Payment and Salary Increase, the “Retention Compensation”). The 

	 	
Retention Grant shall vest ratably in equal installments on July 15th and January 15th of each year over the three year period immediately following the grant date, provided that the
Executive maintains a continuous service relationship with the Company through each applicable vesting date. The Retention Grant shall vest in full upon the consummation of a Change in Control (as defined in the Employment Agreement), subject to the
Executive maintaining a continuous service relationship with the Company at such time. The Retention Grant shall be subject in all respects to the RSU Agreement and equity incentive plan provided by the Company. 

 

	2.	 Employment Condition; Consulting Services. 

 

	 	a.	 The Executive agrees to (i) remain employed by the Company through September 30, 2022, unless earlier
terminated by the Company (September 30, 2022, or any such earlier date if the Executive’s employment is earlier terminated by the Company, the “Employment Retention Date”); and (ii) if requested by the Company on or
before the Employment Retention Date, to provide three (3) months of consulting services to the Company, for no more than 20 hours per month (unless otherwise mutually agreed) (such limitation on hours, the “Hours Cap”),
and ending no later than December 31, 2022 (the “Consulting Services,” and the period during which the Executive performs Consulting Services, the “Consulting Period”). During the Consulting Period, the Company
shall pay the Executive a cash hourly rate for each hour worked up to the Hours Cap, with such hourly rate derived by dividing the Executive’s final base salary rate by 2,080. 

 

	 	b.	 The Consulting Services, if any, shall consist of such transition and advisory services as the Company
requests. The Executive agrees that the Executive’s Restrictive Covenant Obligations shall be extended throughout any Consulting Period, such that, for example, any post-employment noncompetition and nonsolicitation periods contained in the
Restrictive Covenant Obligations shall not begin to run until the day following the last day of the Consulting Period. To avoid doubt, the Executive acknowledges and agrees that any Company confidential information to which the Executive gains
access during the Consulting Period shall be subject to the confidentiality obligations contained in the Restrictive Covenant Obligations and that the Executive shall not use or disclose such information except during the Executive’s service
relationship with the Company and in direct furtherance of Executive’s duties to the Company. 

  

	3.	 Retention Period. The period of Executive’s employment with the Company through the Employment
Retention Date and any Consulting Period is the “Retention Period.” 

  

	4.	 Repayment Upon Certain Terminations. 

 

	 	a.	 If the Executive resigns employment, fails to provide the Consulting Services as requested by the Company, or
is terminated by the Company for “Cause” (as defined in the Employment Agreement), in each case on or before June 30, 2022, the Executive shall repay the Retention Payment in full to the Company by no later than July 15,
2022. 

  
 2 

	 	b.	 If the Executive resigns employment or the Executive’s consulting relationship with the Company for any
reason, fails to provide the Consulting Services through, at the latest, December 31, 2022 as requested by the Company, or is terminated by the Company for Cause, in each case between July 1, 2022 and the end of the Retention Period, the
Executive shall repay 50% of the Retention Payment to the Company by no later than fifteen days following the last day of the Executive’s service relationship with the Company. 

 

	5.	 Amendment to Employment Agreement; Waiver and Release. 

 

	 	a.	 Sections 4(b)(i) and 5(a)(i) of the Employment Agreement are hereby deleted and of no further effect, except to
the extent such Sections are expressly amended by and incorporated into Section 6 of this Agreement. 

  

	 	b.	 In consideration of the Retention Compensation and the Executive’s continued at-will employment with the Company, the Executive, on behalf of the Executive and the Executive’s heirs, administrators, representatives, successors and assigns (together the “Releasors”),
voluntarily releases and forever discharges the Company, its affiliated and related entities, its and their respective predecessors, successors and assigns, its and their respective employee benefit plans and fiduciaries of such plans, and the
current and former employees, officers, directors, shareholders, interest holders, managers, advisors, members, partners, investors, attorneys, accountants and agents of each of the foregoing in their official and personal capacities (collectively
referred to as the “Releasees”) generally from all claims, demands, debts, damages and liabilities of every name and nature, known or unknown (“Claims”) that, as of the date when the Executive signs this Agreement,
the Executive or any other Releasor has, ever had, now claims to have or ever claimed to have had against any or all of the Releasees, including without limitation Claims relating to (i) Executive’s employment or other service relationship
with the Company; (ii) Executive’s right to receive or be eligible for severance compensation and severance benefits under Section 4(b) or 5 of the Employment Agreement or any other Company severance plan or severance policy;
(iii) Claims for retention compensation, cash bonus compensation, commission compensation and/or other cash incentive compensation of any kind from the Company; and (iv) Claims for all other wages, bonuses, and commissions and other
compensation and benefits, whether under the Massachusetts Wage Act, M.G.L. c. 149, §§148-150C, or otherwise, in each case except for Excluded Claims (as defined below). 

 

	 	c.	 To avoid doubt, nothing in this Section affects or waives: (i) the Executive’s rights and obligations
under the Company’s applicable equity plan and any written and fully-signed equity or RSU agreement in the form provided by the Company (the “Equity Documents”), which Equity Documents remain in full effect; (ii) the
Executive’s rights to accrued but unused vacation and accrued but 

  
 3 

	 	
unpaid salary from the payroll period during which this Agreement becomes effective; (iii) the Executive’s rights to indemnification and Directors’ and Officers’ liability
insurance from the Company, as set forth in the applicable written agreements, Company bylaws and/or Company insurance policies, as applicable; (iv) the Executive’s rights to accrued and vested benefits under any 401(k) or other ERISA
benefit plan; or (v) the Executive’s rights under the Employment Agreement, except as such Employment Agreement is expressly superseded by this Agreement (and the Executive acknowledges and agrees that the Executive’s rights under
Sections 4(b) and 5 of the Employment Agreement are expressly superseded by this Agreement, and the Executive’s rights under those Sections are hereby waived, except to the extent such Sections are expressly incorporated into Section 6 of
this Agreement) (collectively, “Excluded Claims”). 

  

	6.	 Potential Severance Payments Notwithstanding Amendment, Waiver and Release. Notwithstanding the
preceding Section (“Amendment to Employment Agreement; Waiver and Release”): 

  

	 	a.	 Payments Upon Qualifying Termination. If the Company terminates the Executive’s employment without
Cause, or if the Executive terminates employment for Good Reason (as defined in the Employment Agreement), the Company shall pay the Executive two-thirds of the Executive’s “Severance
Amount” (as defined in the Employment Agreement) reduced by the amount of the Retention Payment, in equal installments over the eight (8) months following the Date of Termination, subject to (I) the requirement that the Executive
sign, return and not revoke the “Release,” as defined and described in the first paragraph of Section 4(b) of the Employment Agreement; and (II) the payment conditions contained in subparagraph 4(b)(iii) of the Employment
Agreement. 

  

	 	b.	 Severance Upon Qualifying Termination Within the 12 Months Following a
Non-Insolvency Change in Control. If the Company terminates the Executive’s employment without Cause, or if the Executive terminates employment for Good Reason, in either case within the 12
month-period immediately following the occurrence of the first event constituting a Change in Control other than a Change in Control that occurs following the commencement, or as a result, of any Insolvency Proceeding, the Company shall pay
the Executive the Executive’s severance benefits as provided in Section 5 of the Employment Agreement, subject to the Employment Agreement’s terms and conditions, but reduced by the amount of the Retention Payment. For purposes of
this Agreement, “Insolvency Proceeding” means (a) a voluntary or involuntary case or proceeding under the United States Bankruptcy Code or similar bankruptcy law with respect to the Company; (b) any other voluntary or
involuntary insolvency, reorganization, arrangement or bankruptcy case or proceeding, or any receivership, liquidation, or other similar case or proceeding with respect to the Company or any of its property; (c) a liquidation, dissolution,
reorganization, or winding up of the Company, whether voluntary or involuntary and regardless of whether involving insolvency or bankruptcy; or (d) an assignment for the benefit of creditors or other marshaling of assets and liabilities of the
Company. 

  
 4 

	7.	 Preservation of At-Will Employment. Nothing in this letter
changes the at-will nature of Executive’s employment with the Company. 

  

	8.	 Knowing and Voluntary. The Executive acknowledges and agrees that the Executive has read this Agreement
carefully; that this Agreement affects important legal rights of the Executive; that the Executive has had the opportunity to review this Agreement with legal counsel of the Executive’s choosing; and that the Executive is knowingly and
voluntarily entering into this Agreement. The language used in this Agreement shall be deemed to be the language chosen by the Parties to express their mutual intent, and no rule of strict construction or contra preferendum shall be applied against
either Party. 

  

	9.	 Integration; Absence of Reliance; Preserved Rights and Obligations. This Agreement constitutes the
entire agreement between the Executive and the Company (including all affiliates of the Company) regarding the subject matter of this Agreement, and supersedes any prior or contemporaneous communications, understandings, representations, agreements,
plans or policies of any kind regarding the subject matter of this Agreement. In entering into this Agreement, Executive agrees that Executive is not relying on any promises or representations of the Company (including any Company employee, officer,
director, or other agent) regarding the subject matter of this Agreement except as are expressly set forth herein. This Agreement’s WHEREAS clauses are incorporated herein as operative provisions of this Agreement. To avoid doubt, this
Agreement does not affect the Restrictive Covenant Obligations, the Equity Documents, or those provisions of the Employment Agreement not specifically amended by this Agreement. The Executive specifically agrees that the Company shall, in addition
to its rights and remedies hereunder, and to the fullest extent permitted by applicable law, have the right to: (i) offset any amounts the Executive owes the Company under this Agreement against any compensation or benefits the Company owes the
Executive; and (ii) deduct any amounts the Executive owes the Company under this Agreement from the Executive’s wages. 

  

	10.	 Governing Law; Jurisdiction; Amendment and Waiver; Headings. This letter shall be governed by
Massachusetts law, excluding laws relating to conflicts or choice of law. Executive and the Company submit to the personal jurisdiction and venue of the federal and state courts located in Massachusetts in connection with any dispute relating to
this Agreement or the subject matter of this Agreement, and hereby waive any right to a jury with respect to any such dispute. This letter may not be modified or amended, and no breach shall be deemed to be waived, unless agreed to in writing by
Executive and the Chairperson of the Company’s Board. Any Section and subsection headings are for descriptive, non-operative purposes only, and to the extent such headings conflict with this
Agreement’s non-heading text, the non-heading text shall control. 

  

	11.	 Assignment. The Company may assign its rights and obligations under this Agreement without the
Executive’s consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets. The
Executive may not assign this Agreement. 

  
 5 

	12.	 409A; Taxes. It is intended that the benefits provided under this Agreement shall comply with the
provisions of Section 409A of the Internal Revenue Code (“Section 409A”) or qualify for an exemption to Section 409A, and this Agreement shall be construed and interpreted in accordance with such
intent. Any payments that qualify for the “short term deferral” exception or another exception under Section 409A shall be paid under the applicable exception. Each payment provided under this Agreement shall be treated as a
separate payment for Section 409A purposes. Neither the Company (or its affiliates) or any employee, officer or director of the Company (or its affiliates) shall be held liable for any taxes, interest, penalties or other monetary amounts
owed by Executive as a result of this Agreement. All compensation described in this Agreement shall be subject to applicable taxes and lawful withholdings. 

  

	13.	 Not Good Reason. The Executive agrees that neither this Agreement or the changes to Executive’s
employment contained herein constitute “Good Reason” as defined in the Employment Agreement and the Executive hereby waives any right to claim Good Reason as a result of this Agreement. 

 

	14.	 Deadline for Return. To accept this Agreement, Executive must return a signed original or a signed PDF
copy (DocuSign is acceptable) of this Agreement so that it is received by the Company no later than 7 days after the date of this Agreement. 

  
 6 

 Accepted and Agreed:. 
  

							
	ALLENA PHARMACEUTICALS, INC.	 		 		 	
				
	 /s/ Gino Santini
	 	                                     
                                         
              	 		 	 1/27/22

	Gino Santini	 		 		 	DATE
	Lead Independent Director	 		 		 	
				
	EXECUTIVE	 		 		 	
				
	 /s/ Louis Brenner
	 		 		 	 1/26/22

	Louis Brenner, M.D.	 		 		 	DATE

  
 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]